What is the recommended diagnostic work‑up and first‑line treatment (including dosing) for absence seizures in children and adolescents?

Absence Seizures: Diagnostic Work-up and First-Line Treatment

For childhood absence epilepsy, ethosuximide is the first-line treatment of choice when absence seizures occur in isolation, based on superior efficacy and tolerability compared to alternatives.

Diagnostic Work-up

The diagnosis of absence seizures can be established efficiently through:

Clinical Assessment

• Seizure characteristics to identify: Brief (seconds-long) episodes of impaired consciousness with sudden onset and termination, often with subtle motor manifestations like eyelid myoclonia or mild automatisms
• Provocative testing: Perform prolonged hyperventilation for 3-5 minutes during the office visit—this triggers absence seizures in approximately 90% of untreated patients 1, 2
• Family history: Document any relatives with epilepsy, particularly generalized epilepsy syndromes

Electroencephalography (EEG)

• Routine EEG with hyperventilation is the essential diagnostic test
• Characteristic pattern: Generalized 3-4 Hz spike-and-wave or polyspike-and-wave discharges that are bilaterally synchronous and symmetric 1, 2
• The ictal discharge typically lasts 2-30 seconds and correlates with clinical impairment of consciousness

Additional Testing

• Neuroimaging (MRI) is generally not required for typical childhood absence epilepsy with normal neurological examination and characteristic EEG findings 3
• Laboratory studies are not routinely indicated unless there are atypical features suggesting metabolic or genetic etiologies

First-Line Treatment

Ethosuximide (Preferred for Absence-Only Seizures)

Ethosuximide should be the initial treatment when absence seizures are the only seizure type 1, 4. This recommendation is based on:

• Efficacy: Controls absence seizures in approximately 70% of patients 2
• Superior tolerability: Fewer adverse effects compared to valproic acid 1
• Evidence base: Direct comparative trials demonstrate better risk-benefit profile than alternatives for pure absence epilepsy

Dosing:

• Starting dose: 250 mg once daily (or 10-15 mg/kg/day)
• Titration: Increase by 250 mg every 5-7 days as tolerated
• Target dose: 15-40 mg/kg/day divided twice daily
• Typical maintenance: 500-1500 mg/day (maximum 2000 mg/day)

Important caveat: Ethosuximide does NOT protect against generalized tonic-clonic seizures (GTCS) or myoclonic jerks, so it is unsuitable as monotherapy if these coexist 2.

Alternative First-Line Options

Valproic Acid should be considered when:

• Absence seizures coexist with GTCS or myoclonic jerks
• Controls absences in 75%, GTCS in 70%, and myoclonic jerks in 75% 2

Dosing:

• Starting dose: 10-15 mg/kg/day divided twice daily
• Target dose: 20-30 mg/kg/day (typically 750-2000 mg/day)
• Major limitation: Teratogenicity, weight gain, and metabolic effects make it less desirable, particularly for adolescent females 1, 2

Lamotrigine is a third option but:

• Less effective than ethosuximide (controls 50-60% of absences) 2, 4
• May worsen myoclonic jerks 2
• Risk of serious skin rashes requiring slow titration
• Starting dose: 0.3 mg/kg/day (or 25 mg every other day)
• Titration: Very gradual over 6-8 weeks to minimize rash risk
• Target dose: 5-15 mg/kg/day divided twice daily

Syndrome-Specific Considerations

Childhood Absence Epilepsy (CAE)

• Pure absence seizures predominate
• Ethosuximide monotherapy is optimal 1, 4
• Excellent prognosis with 60-70% achieving remission

Juvenile Absence Epilepsy or Juvenile Myoclonic Epilepsy

• Absences occur with GTCS and/or myoclonic jerks
• Valproic acid is preferred as it addresses all seizure types 2
• Lamotrigine is alternative but avoid if myoclonic jerks present

Treatment Monitoring and Adjustment

• Response assessment: Clinical seizure freedom is the goal; repeat EEG can confirm absence of subclinical discharges
• Refractory cases (fewer than 50% of patients): Consider combination therapy with low-dose lamotrigine added to valproic acid, which may have synergistic effects 2
• Duration: Treatment typically continues for 2-3 years after seizure freedom, then gradual withdrawal may be attempted based on syndrome and EEG normalization

Critical Pitfalls to Avoid

1. Do not use carbamazepine, phenytoin, or other sodium channel blockers—these can worsen absence seizures
2. Do not rely on patient/caregiver seizure diaries—sensitivity is only 8% as most absences go unnoticed 5
3. Do not use ethosuximide monotherapy if GTCS have occurred or are likely based on syndrome (e.g., juvenile myoclonic epilepsy)
4. Do not assume all "staring spells" are absence seizures—confirm with EEG and hyperventilation testing to exclude focal seizures with impaired awareness